<DOC>
	<DOCNO>NCT01908777</DOCNO>
	<brief_summary>The purpose study test benefit chemotherapy drug call romidepsin patient T Cell Non-Hodgkin Lymphoma ( T NHL ) undergo autologous transplantation .</brief_summary>
	<brief_title>A Phase 2 Multicenter Study High Dose Chemotherapy With Autologous Stem Cell Transplant Followed Maintenance Therapy With Romidepsin Treatment T Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>The primary aim determine preliminary estimate progression-free survival patient T NHL receive maintenance romidepsin 2 year post-transplant patient transplant CR1 PR1 standard risk histology . Secondary aim include : - Determine PFS 2 yr patient transplant ≥CR/PR2 patient high risk histology . - Determine toxicity associate romidepsin follow autologous transplantation - Determine probability OS 2 year post transplant patient undergo transplant - Characterize effect romidepsin immune recovery post HDT-ASCT - OS PFS 1 year Romidespin completion</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Age : Patients age 16 deem eligible transplant treat physician Disease status : CR PR require . Remission status assess completion induction chemotherapy prior enrollment protocol . Diagnosis : The follow histology need confirm MSK locally participate site order consider HDTASCT posttransplant maintenance romidepsin : PTCL AITL ALCL EaTCL Hepatosplenic Gamma Delta T cell lymphoma Adult Tcell leukemia/lymphoma Primary cutaneous gamma/delta Tcell lymphoma Extranodal NK/Tcell lymphoma , nasal type Primary cutaneous anaplastic large cell lymphoma Subcutaneous panniculitislike Tcell lymphoma Mycosis fungoides/sezary syndrome Stem cell collection : A minimum 2 x 106 CD34+ cell must collect Laboratory test result within range : Total bilirubin &lt; = 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) &lt; = 3 x ULN Diagnosis : progressive disease transplant workup Prior therapy : prior autologous allogeneic transplant Active uncontrolled infection time transplantation include active infection Aspergillus mold , HIV infection Inadequate performance status/organ function define DLCO &lt; 50 % ( adjust hgb ) , cardiac function define , KPS &lt; 60 % . Pregnant breast feeding . For male female childproducing potential , inability use effective contraceptive method study Prior therapy romidepsin Central nervous system meningeal involvement Any known cardiac abnormality : Congenital long QT syndrome QTc interval ≥ 500 millisecond Myocardial infarction within 6 month transplantation . Subjects history myocardial infarction 6 12 month prior transplant asymptomatic negative cardiac risk assessment ( treadmill stress test , nuclear medicine stress test , stress echocardiogram ) since event may participate Other significant ECG abnormality include 2nd degree atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) Symptomatic coronary artery disease ( CAD ) , e.g. , angina Canadian Class IIIV ( see Appendix 1 ) In patient doubt , patient stress image study , abnormal , angiography define whether CAD present An ECG record screen show evidence cardiac ischemia ( ST depression ≥2 mm , measure isoelectric line ST segment ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition ( see Appendix 2 ) and/or ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram and/or MRI A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) Hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause Uncontrolled hypertension , define blood pressure ( BP ) ≥160/95 ; patient history hypertension control medication must stable dose ( least one month ) meet inclusion criterion Any cardiac arrhythmia require antiarrhythmic medication ( exclude stable dos betablockers ) Patients take drug lead significant QT prolongation within specified wash period ( See Appendix 3 : Medications That May Cause QTc Prolongation ) . Concomitant use CYP3A4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>